Robert Bona, MD
Professor of Medicine (Hematology)Cards
About
Research
Publications
2025
Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis
Glaeser-Khan S, Ito S, Sra M, Richmond R, Bona R, Krumholz H, Croteau S, Cuker A, Goshua G. Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis. Blood Advances 2025, 9: 6237-6245. PMID: 40795232, PMCID: PMC12744270, DOI: 10.1182/bloodadvances.2025016822.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioSevere hemophilia AIntracranial hemorrhageEmicizumab prophylaxisHemophilia ASevere HAWTP thresholdStandard careProphylactic factor replacementUS societal perspectiveInfants Aged 0Markov cohort modelLifetime time horizonCost-effectiveness ratioProbabilistic sensitivity analysesFVIII inhibitorsBleeding riskFactor replacementSevere complicationsEmicizumabAccess placementCentral venous access placementPrimary outcomeProphylaxisNeurological disabilitySuccessful treatment of Kimura disease with Mycophenolate Mofetil: a report of two cases and review of the literature
Wilson M, Hsia C, Rowan K, Huang S, Ng T, Zypchen L, Bona R, Dehghan N, Chen L. Successful treatment of Kimura disease with Mycophenolate Mofetil: a report of two cases and review of the literature. Rheumatology International 2025, 45: 224. PMID: 40924180, DOI: 10.1007/s00296-025-05985-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMycophenolate mofetilSevere Raynaud's phenomenonPeripheral eosinophiliaKimura's diseaseTreatment of Kimura's diseaseTreated with mycophenolate mofetilCombination of mycophenolate mofetilElevated serum IgE levelsDose of prednisoneSerum IgE levelsChronic inflammatory diseaseErythematous papular lesionsCervical lymphadenopathyTolerated therapyDiffuse lymphadenopathySystemic corticosteroidsRare conditionTreatment optionsEpithelioid hemangiomaMembranous nephropathyRaynaud's phenomenonIgE levelsLymphadenopathyInadequate responseInflammatory diseasesCost-effectiveness of prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in patients with severe hemophilia A
Ito S, Potnis K, Harvey J, Sra M, Bewersdorf J, Bona R, Krumholz H, Cuker A, Pandya A, Goshua G. Cost-effectiveness of prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in patients with severe hemophilia A. Annals Of Internal Medicine 2025, 178: 819-828. PMID: 40258278, PMCID: PMC12170149, DOI: 10.7326/annals-24-02749.Peer-Reviewed Original ResearchConceptsEquity weightsSevere hemophilia AInequality aversion parameterFactor VIIIHemophilia AAversion parameterCost-effectiveness analysisEquity standardsCost-effectiveness of prophylaxisTime horizonOnce-weekly prophylaxisPriceAnnualized bleeding rateIncremental cost-effectiveness ratioFactor VIII prophylaxisScenario analysisCost-effectiveness ratioUnited StatesLifetime QALYsBleeding rateProphylaxisNational Institutes of HealthCost-effectiveInstitutes of HealthAlfaTechnology Spotlight New Dimensions for Platelet Evaluation in Hematology Diagnostics
Gu S, Bona R, Hwa J. Technology Spotlight New Dimensions for Platelet Evaluation in Hematology Diagnostics. The Hematologist 2025, 22 DOI: 10.1182/hem.v22.3.202538.Peer-Reviewed Original Research
2024
Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityCost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States
Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States. Blood 2024, 143: 2332-2335. PMID: 38635764, PMCID: PMC11862817, DOI: 10.1182/blood.2024024209.Peer-Reviewed Original ResearchJoint bleeds in mild hemophilia: Prevalence and clinical characteristics
Chiari J, Prozora S, Feinn R, Louizos E, Gallagher P, Bona R. Joint bleeds in mild hemophilia: Prevalence and clinical characteristics. Haemophilia 2024, 30: 331-335. PMID: 38240020, DOI: 10.1111/hae.14939.Peer-Reviewed Original ResearchMild haemophiliaJoint bleedsJoint range of motionHepatitis CRange of motionMild diseaseHistory of joint bleedsInstitutional review board approvalJoint rangeRetrospective chart reviewHemophilia treatment centersReview board approvalJoint healthHistory of traumaDisease burdenMedical recordsChart reviewClinical characteristicsMitigate disease burdenRisk factorsBoard approvalBleedingTraumatic bleedingAverage ageHemophilic arthropathy
2023
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.Commentaries, Editorials and Letters
2021
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis
Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang SY, Price C, Bona RD, Chaar C, Chun HJ, Pine AB, Rinder HM, Siner JM, Neuberg DS, Owusu KA, Lee AI. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis. American Journal Of Hematology 2021, 96: 471-479. PMID: 33476420, PMCID: PMC8013588, DOI: 10.1002/ajh.26102.Peer-Reviewed Original ResearchConceptsProphylactic-dose anticoagulationAntiplatelet therapyHospital deathCumulative incidenceMultivariable regression modelsHospital mortalityHospitalized adult COVID-19 patientsAdult COVID-19 patientsPropensity score-matched patientsPropensity score-matched analysisCOVID-19Intensive antithrombotic therapyIntermediate-dose anticoagulationCohort of patientsCOVID-19 patientsPatient-specific covariatesAnticoagulation cohortAspirin cohortDose anticoagulationAntithrombotic therapyThrombotic complicationsHospitalized patientsPrimary outcomeIllness severityRegression models
2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patients
Clinical Care
Overview
Robert Bona, MD, is a Yale Cancer Center hematologist. He cares for individuals with blood disorders, including those with excessive bleeding or clotting, those with low red blood cell (anemia), low platelet, or white cell counts, and those with disorders of iron metabolism. He is medical director of the Yale Hemophilia Treatment Center.
Dr. Bona says he has been interested in blood disorders since medical school, where he studied with some of the top experts in the field. “I’ve always been interested in looking at blood cells under the microscope and studying blood coagulation and clotting,” he says.
As a Yale Medicine clinician, he often works with teams that include advanced practitioners, nurses, and other specialized physicians from medicine, laboratory medicine, and transfusion medicine, as well as medical providers from related areas such as surgery and radiology.
For those individuals asking for advice or care, he suggests they come to their visit with a sense of what they want to talk about. “Come with an agenda. It might be to discuss your diagnosis, treatment for your disease, or other diagnostic possibilities if the diagnosis has not yet been made,” he says. If you are coming from a medical center with a different medical record system, making your complete medical record available is important to have an optimal visit. It also helps, if you wish, to bring a family member or friend to talk to us about complex medical issues.”
In addition to his clinical work, Dr. Bona is a professor of medicine (hematology) at Yale School of Medicine. He has strong interests in medical education and research interests in new treatments for people with bleeding or clotting disorders. “The education and training of our next generation of physicians and medical educators is very important to me,” he says.
Prior to coming to Yale, Dr. Bona was a founding faculty member of the Frank H. Netter MD School of Medicine at Quinnipiac University. Prior to that, he worked in the Hematology-Oncology division at the University of Connecticut.
Clinical Specialties
Fact Sheets
Anemia
Learn More on Yale MedicineCerebral Venous Sinus Thrombosis (CVST)
Learn More on Yale MedicineBleeding Disorders
Learn More on Yale MedicineDeep Vein Thrombosis
Learn More on Yale Medicine
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2015
- Original Certification Date
- 1986
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1985
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1983
Yale Medicine News
News & Links
News
- December 05, 2024
Drug Offers Cost-Effective Protection for Newborns with Genetic Bleeding Disorder
- April 30, 2024Source: Mint
Thrombosis Thrombocytopenia Syndrome: Symptoms of TTS. Rare Side-Effect of AstraZeneca Covid Vaccine Explained
- March 25, 2024
Yale’s Post ASH Review
- February 15, 2024
Educational Exchange Brings Ugandan Hematologist Dr. Christine Sekaggya-Wiltshire to Yale School of Medicine
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.